Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Research & Development (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Research & Development for 12 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 22.93% year-over-year to $2.0 million, compared with a TTM value of $9.8 million through Sep 2025, down 14.32%, and an annual FY2024 reading of $11.3 million, down 10.99% over the prior year.
  • Research & Development was $2.0 million for Q3 2025 at Lisata Therapeutics, down from $2.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $3.4 million in Q3 2023 and bottomed at $2.0 million in Q3 2025.
  • Average Research & Development over 3 years is $2.8 million, with a median of $2.9 million recorded in 2024.
  • Peak annual rise in Research & Development hit 1.95% in 2024, while the deepest fall reached 24.79% in 2024.
  • Year by year, Research & Development stood at $3.0 million in 2023, then dropped by 2.09% to $2.9 million in 2024, then plummeted by 33.59% to $2.0 million in 2025.
  • Business Quant data shows Research & Development for LSTA at $2.0 million in Q3 2025, $2.3 million in Q2 2025, and $2.6 million in Q1 2025.